Bloomberg -- Ratiopharm GmbH, the generic-drug maker being sold by Germany’s Merckle family to pay off loans, drew bids of about 2 billion euros ($3 billion) from companies including TPG Inc., Goldman Sachs Group Inc. and Advent International Corp., two people close to the matter said.
